Form 10-Q - Quarterly report [Sections 13 or 15(d)]

S&P ASX All Technology

US Dollar vs AUD

Level up your trading with our powerful tools and real-time insights all in one place.

Get Started

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Article too big to display. Click here to view on the SEC website

PAVmed (NASDAQ:PAVM)
Historical Stock Chart
From Dec 2024 to Jan 2025

Click Here for more PAVmed Charts.

PAVmed (NASDAQ:PAVM)
Historical Stock Chart
From Jan 2024 to Jan 2025

Click Here for more PAVmed Charts.

PAVmed Inc News

Lucid Diagnostics Announces Record Quarterly EsoGuard® Test Volume
Monday 13 January 2025 (2 weeks ago) • PR Newswire (US)

Lucid Diagnostics Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Rule
Tuesday 24 December 2024 (1 month ago) • PR Newswire (US)

Lucid Diagnostics Partners with VITALExam to Enhance Esophageal Precancer Detection for Firefighters
Friday 20 December 2024 (1 month ago) • PR Newswire (US)

Prospective Clinical Utility Study of Lucid Diagnostics' EsoGuard® Esophageal DNA Test Accepted for Peer-Reviewed Publication
Thursday 12 December 2024 (2 months ago) • PR Newswire (US)

Lucid Diagnostics Completes Convertible Debt Refinancing to Strengthen Balance Sheet and Extend Cash Runway Past Key Near-Term Milestones
Wednesday 4 December 2024 (2 months ago) • PR Newswire (US)

Lucid Diagnostics Submits Clinical Evidence Package to MolDX Seeking Medicare Coverage for EsoGuard® Esophageal DNA Test
Wednesday 20 November 2024 (2 months ago) • PR Newswire (US)

Lucid Diagnostics to Present at the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum
Tuesday 19 November 2024 (2 months ago) • PR Newswire (US)

PAVmed Provides Business Update and Third Quarter 2024 Financial Results
Friday 15 November 2024 (2 months ago) • PR Newswire (US)

Lucid Diagnostics' ESOGUARD BE-1 Prospective Multicenter Clinical Validation Study of EsoGuard® Esophageal Precancer Testing Accepted for Peer-Reviewed Publication
Friday 8 November 2024 (3 months ago) • PR Newswire (US)

Lucid Diagnostics Expands Direct Contracting Initiative with Multiple Programs Focused on Near-Term Revenue Drivers
Wednesday 6 November 2024 (3 months ago) • PR Newswire (US)

PAVmed to Hold a Business Update Conference Call and Webcast on November 14, 2024
Thursday 31 October 2024 (3 months ago) • PR Newswire (US)

Lucid Diagnostics to Hold a Business Update Conference Call and Webcast on November 13, 2024
Wednesday 30 October 2024 (3 months ago) • PR Newswire (US)

More PAVmed Inc News Articles

KBC Bank NV 0.75% 08mar2...

Delayed Upgrade Clock

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions